The Peptide AppField Guide · Longevity SeriesField Specimen

Longevity Category

Prostamax

Name: Prostamax: Uses, Evidence & Safety
Creator: The Peptide App
Published: 2026-01-27T18:38:35.818468+00:00

THE PROSTATE HEALER

Prostate Peptide Complex

Prostamax is a bioregulator peptide complex derived from prostate tissue that helps restore healthy prostate structure and function. It works by modulating gene expression in prostate cells, reducing inflammation, and supporting hormonal balance. It's used to manage symptoms of BPH (benign prostatic hyperplasia) and prostatitis, improving urinary comfort and flow.

Prostamax

Prostamax Evidence Snapshot

How these guides are reviewed

Regulatory status: Not FDA approved · research use only
Dosing guidance: Reviewed by our clinical team
Linked evidence: 3 research sources
Content updated: May 8, 2026

Dose and schedule recommendations shown below come from The Peptide App Clinical Team. Research links are provided so readers can inspect the supporting evidence directly. Review the sources.

Quick Answers About Prostamax

Is Prostamax FDA approved?

No. This profile records Prostamax as not FDA approved and for research use only.

More context

Review the regulatory and source details on this page for the current context.

What dose does The Peptide App Clinical Team recommend for Prostamax?

Dose: 20 mg daily (oral or subcutaneous).

More context

Schedule: daily. Cycle: 4 weeks on, 16 weeks off. This is clinical-team guidance for reference and does not replace individualized instructions from a licensed clinician.

What research supports this Prostamax guide?

This guide links to 3 curated or current research sources.

More context

Open the research section to inspect the source titles, publication details, study types, and available abstracts directly.

Review the Prostamax research sources

Studied Effects & Mechanisms

Gene Regulation

Enhances histone acetylation in prostate epithelial cells

Androgen Modulation

Balances androgen receptor signaling and DHT sensitivity

Anti-Inflammatory

Reduces NF-κB activation and inflammatory cytokines

Tissue Normalization

Promotes healthy prostate cell structure

Clinical & Research Context

Men over 50 with prostate concerns

Those with benign prostatic hyperplasia (BPH)

Men experiencing prostatitis

Anyone wanting to support prostate health proactively

Those with urinary flow issues

Prostamax Dosing

Dosage

20 mg daily (oral or subcutaneous)

Schedule

daily

Cycle

4 weeks on, 16 weeks off

Clinical Team Note

Take in the morning to align with hormonal patterns

Get your exact syringe units with the reconstitution calculator

Clinical Team Dosing Guidance

Reported Timeline

Week 1-2

Peptide begins modulating gene expression

Week 2-3

Reduced inflammation and improved comfort

Week 4

Improved urinary flow and prostate function

Urinary improvements may be noticed within 2-4 weeks.

Timelines summarize reported or expected patterns and are not guaranteed individual outcomes.

Clinical Safety Context

Excellent Safety

Editorial grade A · Excellent

SafetyAExcellent

FDA approval statusNo · research use only

No common side effects reported. Well tolerated.

Not for use if prostate cancer is suspected. Does not replace PSA screening.

Possible side effects

Rare transient hormonal fluctuations

How to interpret safety grades

The Peptide App

Set up your Prostamax schedule

Dose reminders and your schedule, ready the moment you open the app.

Research-Market Price Snapshot

A compact market signal for this profile. The dedicated pricing page owns vendor, vial-size, and price-per-mg comparisons.

Updated Jul 16, 2026

Vendors: 12
Listings: 13
Observed range: $32–$99

Compare all Prostamax prices →

Prostamax Research

Live PubMed intelligence from the research crawler

PMID 19359734UnknownRelevance 41

Microcalorimetric study of human blood lymphocytes culture at presence of copper, cadmium and prostamax.

Georgian medical news · Mar 1, 2009

Research goal was study of separate and joint influence of bioregulator prostamax and Cu(II) and Cd(II) ions on the chromatin structure in situ. The thermal characteristics of the denaturation process of blood lymphocytes culture of aging people in the presence of some microg quantities of Cu(II) and Cd(II) ions have been determined. It has been shown that Cu(II) and Cd(II) ions at these low concentrations don't influence on the temperature stability of membrane, nuclear and cytoplasm proteins. It has been shown that Cu(II) ions cause an additional condensation of the heterochromatin, and Cd(II) ions cause decondensation of heterochromatin and its partial denaturation.

PMID 15612551UnknownRelevance 41

[The influence of the peptide bioregulator prostamax on heterochromatin of human lymphocytes in situ].

Biofizika · Jan 1, 2004

It was shown that chromatin contained in human lymphocytes has two stages of denaturation: with T(d)VII = 94.4 degrees C, Q(d)VII = 50.8 J/g DNA, and T(d)VIII = 105.1 degrees C Q(d)VIII = 44.9 J/g DNA. The peptide bioregulator prostamax causes a redistribution of heat among endotherms T(d)III and T(d)IV and a shift of both endotherms to low temperatures by 2.9 and 1.0 degrees C, respectively. It was supposed that the redistribution of heat among endotherms is connected with a partial relaxation of the 30-nm-thick fiber in the 10-nm filament. A weak decrease in T(d)VIII and T(d)VII of lymphocytes treated with prostamax compared to untreated ones is connected with small structural changes of nucleosomal organization in the 10-nm filament and 30-nm-thick fiber.